A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, Jr., Freemantle, N., Mason, J., Eccles, M., & Boynton, J. (1999) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 107
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 25
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Items 401–500 of 510
Bupropion XL Use in Comorbidity of Depression and Restless Leg Syndrome: A Case Report
Durmaz, O., & Ateş, M. A. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20131105021804 · Cited by 1
Effects of acute intra-hippocompal injection of bupropion on active avoidance learning in rats
ghaedrpour, S., Zare, S., & Pakdel, F. G. (2010) · Cited by 1
Smithson, J., & Mitchell, P. B. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.06.013 · Cited by 2
Efectos del bupropión sobre depresión, ansiedad y abstinencia a nicotina
Hernández-Lozano, M., Gutiérrez‐García, A. G., Contreras, C. M., & López, G. A. (2010) · Archivos de Neurociencias · Cited by 2
Bupropion: The Antidepressant of Choice for Vitiligo Patients?
Nozari, F. (2018) · Journal of Clinical Research in Dermatology · Cited by 2
Machen Antidepressiva doch abhängig? – Kontra
Messer, T. (2018) · Psychiatrische Praxis · doi:10.1055/a-0723-8338 · Cited by 1
Hoz, F. J. E. D. L. (2018) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2018.02.00105 · Cited by 1
Tics of Trauma: Unique Case of Trauma-Associated Psychogenic Tics in an Adolescent Patient
Ku, J., Koo, C., & Patel, V. (2021) · Cureus · doi:10.7759/cureus.17652 · Cited by 1
Practice patterns of bupropion co-prescription with antipsychotic medications
Gautam, M., Patel, S. R., & Zarkowski, P. A. (2022) · Journal of Addictive Diseases · doi:10.1080/10550887.2022.2028531 · Cited by 1
Role of Medicinal Plants in Combating Anti-depressant Induced Male Infertility
Raval, M., Gori, P., Patel, S. G., & Vyas, N. Y. (2022) · Current Traditional Medicine · doi:10.2174/2215083808666220321144217 · Cited by 3
https://promedsci.org/articles/Propofol%20as%20a%20Rare%20Cause%20of%20Serotonin%20Syndrome
Malik, Z. R. (2021) · Progress in Medical Sciences · doi:10.47363/pms/2021(5)152 · Cited by 1
Olivier, B., Breuer, M. E., Vinkers, C. H., & Olivier, J. D. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109932 · Cited by 2
Pharmaceutical Agents for Areca Nut Cessation
Sumithrarachchi, S., & Jayasinghe, R. D. (2023) · Textbooks in contemporary dentistry · doi:10.1007/978-3-031-12855-4_21 · Cited by 1
Uso de Bupropiona para Tratamento do Transtorno de Déficit de Atenção/Hiperatividade (TDAH)
Procópio, J. V. V., Baltazar, B. T., Fidelis, G. P., Gomes, F. W. C., Lacerda, M. V. L. B., Gomes, C. H. F. D. M., Moreira, A. F. C. M., Feitosa, A. D. N. A., Abreu, H. M. B. F., & Neto, M. C. D. B. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e13173.2023 · Cited by 2
The effect of substance misuse on HIV persistence in the CNS
LuPone, T., Duyne, R. V., O’Brien, E. V., Matt, S. M., Dampier, W., Nonnemacher, M. R., Wigdahl, B. L., Gaskill, P. J., & Klase, Z. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00022-5 · Cited by 1
FARFOOD: a database of potential interactions between food compounds and drugs
Nevado-Bulnes, A. M., Benitez, D. A., Cumplido-Laso, G., Carvajal-González, J. M., Mulero‐Navarro, S., & Román, Á. (2025) · BioData Mining · doi:10.1186/s13040-025-00493-2 · Cited by 1
“Its mechanism of action involves the selective inhibition of catecholamine reuptake, specifically norepinephrine and dopamine, with minimal effect on serotonin reuptake and no inhibition of monoamine oxidase (Stahl et al., 2004).”
In search of animal models for male sexual dysfunction
Chan, J. S. W. (2008) · Utrecht University Repository (Utrecht University) · Cited by 1
Challenges in diagnosing pathological anxiety
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.009 · Cited by 1
Lazowski, L. (2009) · QSpace (Queen's University Library) · Cited by 1
Elmabruk, A. S. M. (2018) · Human Biology · Cited by 1
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23672-3.00005-6 · Cited by 1
The role of IL-6 in dopamine dysregulation underlying anhedonia phenotype in ratsPreprint
Varela, R. B., Macpherson, H. K., Houghton, T., Daygon, V. D., & Tye, S. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.21.568169 · Cited by 1
“Bupropion is an aminoketone antidepressant which acts by weakly inhibiting reuptake of DA and norepinephrine, with efficacy similar to classical antidepressants [32].”
BackgroundMultimodal MR Prediction Models for Late-Life Depression and Treatment Response
Patel, M. J. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
Ruokahalun säätely ja lihavuuden lääkehoito : lihavuuslääkkeiden tehoseulontamenetelmä seeprakalalla
Heine, S. (2014) · Helda - University of Helsinki Institutional Repository
Cigarette smoking and schizophrenia
Patrick, J. A. (2007) · ERA
Efecto del bupropión sobre la cognición de personas con trastorno depresivo
Herrera‐Guzmán, I., Montoya, K. P. A., & Gudayol‐Ferré, E. (2011) · Ciencia Nicolaita
Management Options for Hot Flashes in Cancer Patients
Moraska, A. R., & Loprinzi, C. L. (2013) · Wiley eBooks · doi:10.1002/9781118590638.ch13
Central fatigue during exercise: potential manuipulations and limiting factors
Hobson, R. M. (2010) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Issues and Clues in the Pharmacological Treatment of Mood Disorders
Jollant, F., Ionita, A., & Courtet, P. (2010) · Wiley eBooks · doi:10.1002/9780470749180.ch6
The Role of Bupropion in the Management of Major Depressive Disorder
Ha, K., Tawadros, Y., & IsHak, W. W. (2011) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s20
Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines
Forsyth, A. N. (2012) · ScholarWorks @ The University of New Orleans (The University of New Orleans)
Bupropion in the treatment of major depressive disorder: a comparison with paroxetine
Calandra, C., Terranova, F., Loiacono, P., Caudullo, V., Russo, R., Luca, M., & Cafiso, M. (2010) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
Gedge, L. (2010) · QSpace (Queen's University Library)
A Case of Transient Psychosis after Sustained Release Bupropion Overdose
나경세, 이소영, & 정한용 (2011) · 대한정신약물학회지
Chiu, V. M. (2012) · Research Exchange (Washington State University)
EFFECTS OF LONG TERM PERINATAL TREATMENT OF BUPROPION ON LTP IN NEONATAL RAT HIPPOCAMPUS SLICES
Pakdel, F. G., Zare, S. H., Heysieattalab, S., & Hashtjini, M. M. (2010)
Vasar, V., Maron, E., Eller, T., & Nutt, D. J. (2009) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.10603
CNS demyelination after treatment with bupropion
(2009) · The Internet Journal of Neurology · doi:10.5580/dc6
The Effect of AST-120 on Hepatic Metabolism and Transport in Chronic Kidney Disease
Kucey, A. S. (2016) · Scholarship@Western (Western University)
Masters, A. R. (2016) · IUScholarWorks (Indiana University) · doi:10.7912/c2/318
Fox-Loe, A. M. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.461
“Bupropion, originally marketed as an antidepressant in 1989, has also been approved as a smoking cessation agent [180, 181].”
BackgroundZhang, J. (2017) · TSpace (University of Toronto) · Cited by 1
이가원, Lee, K., Park, Y., Hun, L. J., Koo, B., Lee, S., Mo, S. H., & Cheon, E. (2017) · Anxiety and Mood · doi:10.24986/anxmod.2017.13.2.003
Noradrenaline dopamine-reuptake inhibitors
Silverstone, P. H. (2012) · doi:10.2217/ebo.11.262
Sadness/Demoralisation and Apathy
Picardi, A., Gaetano, P., & Fabi, E. (2018) · Springer eBooks · doi:10.1007/978-3-319-78202-7_6
Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction
Abdo, C. H. N. (2018) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-68306-5_20
Wartko, P. D. (2018) · ResearchWorks at the University of Washington (University of Washington)
Camacho, M. B. (2018) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
“In contrast, therapeutically relevant doses of bupropion occupy 15-25% of DAT and do not alter responses on the tyramine pressor test (a proxy of NET inhibition; Gobbi et al., 2003; Stahl et al., 2004).”
BackgroundSmoking Cessation: Breaking the Strong Addiction
Neptune, E., Leone, F. T., & Kathuria, H. (2020) · Respiratory medicine · doi:10.1007/978-3-030-44889-9_14
Bupropion overdose as a clinically significant confounder of the neurological examination
Reyes, R. G., & Figueroa, S. A. (2020) · Journal of Neurocritical Care · doi:10.18700/jnc.200021
“It also has adjunct benefits for neuropathic pain, smoking cessation, and weight loss [1].”
BackgroundUnger, K. (2019) · Lu Zone Ul (Laurentian University)
Rescuing Dopamine Transporter Deficiency Syndrome
Sutton, C. (2018) · TSpace (University of Toronto)
Antidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_26-1 · Cited by 1
Risk factors and treatment approaches to seasonal affective disorder: a review
Jurgaitytė, V., Khawaja, N., Dijokas, J., & Rimkevičiūtė, P. (2020) · Neurologijos seminarai · doi:10.29014/ns.2020.03
Csatlósová, K., Grinchii, D., Bögi, E., Viñas-Noguera, M., Šimončičová, E., Belovičová, K., Dubovický, M., & Dremencov, E. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.789
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt080
Moradpour, F., Zare, S., & Pakdel, F. G. (2022) · Asian Journal of Biology · doi:10.9734/ajob/2022/v14i230209
“Bupropion is the only newly developed anti-depressant drug available in the United States without serotonergic activity [14].”
Background(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23673-0.00005-7
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-23671-6.00005-5
Wu, P. E., & Juurlink, D. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_135
Moser, P. (2008) · Elsevier eBooks · doi:10.1016/b978-008055232-3.64054-1
Antidepressants: Pharmacology and Biochemistry
Efinger, V., Müller, W. E., & Friedland, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_26 · Cited by 1
Nicotine addiction: The role of specific nAChR subtypes and treatments
Boyd, R. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-819958-9.00006-2
Vadiei, N., Le, A., Lopez, A., Ponciano, A., & Smiley, D. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231168598
“27 Additionally, bupropion ’ s lack of serotonergic activity results in a much lower incidence of nausea, diarrhea, sexual dysfunction, and somnolence compared to SSRIs, 28 – 30 which is signi fi cant considering these are also common side-effects of various chemotherapy agents.”
BackgroundPharmacotherapy of Hypoactive Sexual Desire
Коcharyan, G. S. (2023) · Health of Man · doi:10.30841/2786-7323.2.2023.286438
Chen, X., Xu, Y., Dong, L., Liu, X., Zhang, J., Tang, L., Jing, Y., Guan, Y., & Li, Z. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_16_24
Antinociceptive effect of bupropion on visceral pain and its mechanism of action
Yeşilyurt, İ., SALTIK, Ö. D., & Bozkurt, A. (2024) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1429753
A concise review of pharmacological and nonpharmacologic therapeutics in psychodermatology
Bubna, A. K. (2024) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.4103/jewd.jewd_42_23
Corrigendum: Antinociceptive effect of bupropion on visceral pain and its mechanism of action
Yeşilyurt, İ., & Bozkurt, A. (2024) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1555547
Schindel, B. J., & Shapiro, B. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824060-1.00031-6
Long-Term Impacts of Bupropion Exposure during Critical Developmental Periods on Reward Learning
Smith, S. N. (2024) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2024-16221 · Cited by 1
Volitional Regulation and Transferable Patterns of Midbrain Oscillations
Lu, H., Zhao, Y., Stealey, H. M., Barnett, C. R., Tobler, P. N., & Santacruz, S. R. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1808-24.2025
Adult ADHD: A Comprehensive Overview of Treatment Approaches
Bourin, M. (2025) · Archives of Depression and Anxiety · doi:10.17352/2455-5460.000099
Daliri, E., Hamyani, Z., Arjangi, A., Khakpai, F., Alijanpour, S., & Zarrindast, M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177780
Guin, A., Haokip, H. R., Bandyopadhyay, S., Das, S., Saha, I., Basu, A., & Bhargava, S. (2025) · Indian Journal of Public Health · doi:10.4103/ijph.ijph_400_24
Atypical Manifestations of Bupropion Overdose: A Case Report from A Public Hospital in Macao
Vong, I. C., Miu, C. F., Chang, T. F., & Ieong, K. (2025) · Malaysian Journal of Pharmacy · doi:10.52494/maljpharmv11103
Lata, S., & Nanda, S. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10038-z
“Currently, it is known that bupropion completely lacks serotonergic action and inhibits the absorption of dopamine and norepinephrine [2].”
BUPROPION FOR ADHD: MECHANISMS OF ACTION AND ITS POTENTIAL AS AN ALTERNATIVE TREATMENT — A REVIEW
Narożniak, M., Czerwiec, B., Skowrońska-Borsuk, J., Borsuk, A., Pergoł, J. K., Wojtas, M. M., Pękacka, A. E., Borkowska, J., Krupa, Z., & Sposób, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3664
Unmasking a Rare Adverse Reaction: Acute Kidney Injury Linked to Bupropion Use
Mukherjee, S., & Munshi, S. (2025) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_232_25
Donahue, T. J. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/sy1b-7s46
“Bupropion is categorized as an “atypical” antidepressant as it acts via dual inhibition of norepinephrine and dopamine reuptake with negligent serotonergic effect or effects on post synaptic receptors (Stahl et al., 2004).”
BackgroundCavariani, M. M. (2013) · Americanae (AECID Library)
Applying Quantitative Systems Pharmacology Methods to Study Psychosis in Alzheimer’s Disease
Fan, P. (2023) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Oliveira, M. D. R. P. D. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/gt9s-g349
Carbone, M. G., Mazzetto, L., Miccichè, R., Bellini, A., Rizzato, R., Gastaldello, G., Tagliarini, C., Rocca, F. D., & Maremmani, A. G. I. (2025) · Heroin addiction and related clinical problems · doi:10.62401/2531-4122-2025-31
Revisión del uso de hojas de coca como tratamiento alternativo para el mal agudo de montaña
Gutiérrez, A. C. Q. (2026) · Revista Salud Bosque · doi:10.18270/rsb.5051
Saquilayan, P. (2024) · TSpace (University of Toronto) · Cited by 1
Ghimire, A., Tuey, S. M., Prebehalla, L., Atilano‐Roque, A., Roda, G. F., Thompson, L. E., Chonchol, M. B., Shah, N. A., Wempe, M. F., Nolin, T. D., et al. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/3265655
Singh, B. B., sharma, D., Shingatgeri, V., & Lomash, V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.16.712249
“Bupropion is a dopamine transporter inhibitor employed as an antidepressant to elevate synaptic dopamine levels by obstructing dopamine reuptake (Stahl et al., 2004).”
il cibo cura la mente: neuronutrizione e psichiatria nutrizionale
CELESTINO, R. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Effets à long terme d'une exposition prénatale au méthylphénidate chez le rat
Lepelletier, F.-X. (2013) · theses.fr (ABES) · doi:10.70675/797ccf76zd338z4f31z841az3fd18f272296 · Cited by 1
Rôle des récepteurs 5-HT4 dans la modulation de la plasticité synaptique au sein du gyrus denté
Es-Safi, S. (2025) · theses.fr (ABES) · doi:10.70675/954404efzad5fz445dz86aez41d9d3dd8e65
Dose-related Manic Switch with Psychotic Features Following Bupropion Titration: A Case Report
Tulacı, R. G., Yıldırım, S., Ulusoy, H., & Dolapoğlu, N. (2026) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.26.1402
“One possible explanation is that the dopaminergic and noradrenergic enhancement induced by bupropion may have exceeded the stabilizing capacity of lurasidone ’ s D2 receptor antagonism at this dose [11].”
Anxiety disorders alter cognitive-motor integration during visuomotor adaptation and retention
Barzi, L., Wilson, M., & Hill, C. M. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07304-y
“Bupropion simultaneously elevates both dopamine and norepinephrine in the prefrontal cortex (Stahl et al. 2004).”
Pharmacotherapy for online behavioral addictions: a systematic review
Park, J. J., Chen, B. B., & Potenza, M. N. (2026) · Future Science OA · doi:10.1080/20565623.2026.2681577 · Cited by 1
“…modulation of dopaminergic and noradrenergic signaling within mesocortolimbic pathways implicated in reward sensitivity and cognitive control [60–63], potentially improving top-down regulation of gaming-related urges. considering previous research reporting altered sero-tonergic functioning…”
Chiappini, S., Ricci, V., Filippis, S. D., Quattrone, D., Martinotti, G., on behalf of the Dual Care Study Group, Besana, F., Cutuli, M., Rocca, F. D., Faveretto, E., et al. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2686094
“Dopaminergic agents—such as bupropion—were highlighted for additional benefits in addressing motivational deficits and anhedonia (Stahl et al., 2004) despite their potential for misuse (Schifano and Chiappini, 2018).”
McIntyre, R. S., Kato, M., Thase, M. E., Therrien, F., Marrache, A. M., Ikehara, K., Ardic, F. C., & Boucher, M. (2026) · CNS Drugs · doi:10.1007/s40263-026-01315-7 · Cited by 1
“Recommended as second-line adjunctive treatment with Level 1 evidence in the CANMAT guidelines [15], bupro-pion is a dual inhibitor of NE and DA reuptake, with functional potency for the presynaptic NE and DA transporters [125].”
Oral Agents Used to Treat Type 2 Diabetes and Obesity
Liddle, J., Ratkova, E. L., Bonito, C. A., Rhodes, C. J., & Will, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch5
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.